We and others have demonstrated the correlation of MTA1 expression with clinicopathological measures of prostate cancer progression: high Gleason score, development of castrate‐resistant disease, recurrence, and bone metastasis (Dias et al., 2013a; Hofer et al., 2006; Kai et al., 2011). This evidence concerns the gene MTA1 and prostate cancer.